- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01126450
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
A Phase I, Open-Label Study To Determine The Maximum Tolerated Dose (Mtd) Of The Combination Of Lenalidomide And Cetuximab, And To Evaluate The Efficacy Of This Combination In Subjects With Wild Type K-Ras Metastatic Colorectal Carcinoma
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving lenalidomide together with cetuximab may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when given together with cetuximab in treating patients with metastatic colorectal cancer.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD).
SECONDARY OBJECTIVES:
I. To further explore the safety and efficacy profile.
OUTLINE:
This is a dose-escalation study of lenalidomide.
Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion
- Wild type metastatic colorectal cancer that failed (progressed, refused or not tolerated) on at least two treatment regimens including a fluoropyrimidine, oxaliplatin and irinotecan with or without bevacizumab
- At least 28 days must have lapsed since completion of prior chemotherapy
- Subjects must understand and voluntarily sign an informed consent document
- Subjects must be able to adhere to the study visit schedule and other protocol requirements
- Histological or cytological diagnosis of colorectal carcinoma
- Radiographic or clinical evidence of a measurable disease (by RECIST criteria)
- Subjects must have received prior treatment with at least 2 prior regimens of therapy
- ECOG performance status of =< 1
- Anticipated survival >= 3 months
- Must agree to also take low dose aspirin (or other anticoagulation if unable to take ASA) while receiving study drug and for 30 days after study drug is discontinued
- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 10-14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to ongoing pregnancy testing
- Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy
Exclusion
- Pregnant or lactating females
- CrCl < 50 mL/min by Cock-Croft and Gault
- Any serious medical condition or psychiatric illness that places the subject at an unacceptable risk for study participation or would prevent the subject from signing the informed consent
- Use of any cytotoxic chemotherapy within 28 days of study Day 1
- Use of therapeutic radiation =< 14 days prior to study Day 1
- Use of thalidomide, or structurally related compounds or biologic response modifier therapy within 14 days of study Day 1
- Prior desquamating rash while taking thalidomide, or structurally related compound therapy
- Prior >= Grade 2 allergic reaction to thalidomide or structurally related compounds
- Any prior use of Lenalidomide
- Subjects may have received prior thalidomide
- Known or suspected brain metastases
- Concurrent use or anticipated use of any other anti-cancer agents (except for stable dose steroid use for control of metastases symptoms) during participation in this study
- Absolute Neutrophil Count =< 1500/mm^3 (or 1.5 X10^9/L)
- Platelet Count =< 100,000/mm^3 (or 100 X 10^9/L)
- Hemoglobin < 8.0 g/dL
- Total Bilirubin > 2.0mg/dL
- Alanine Aminotransferase (ALT/SGPT) >= 3 x upper limit of normal (ULN)
- Aspartate Aminotransferase (AST/SGOT) >= 3 x upper limit of normal (ULN)
- Peripheral neuropathy >= Grade 2
- Active infection
- Subjects with an infection that is amenable to curative treatment may be eligible for screening once the infection has been treated, cured and not recurred for at least 14 days
- Uncontrolled hyper- or hypo- calcemia, glycosemia or thyroidism
- Arterial or venous thrombotic event in the preceding six months
- Known history of HIV infection
- Active viral hepatitis who is on active treatment
- No other malignancies, other than previously treated non-melanoma skin cancer or carcinoma insitu of the cervix or breast
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Arm I
Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Dado IV
Otros nombres:
Administrado oralmente
Otros nombres:
Estudios correlativos
Estudios correlativos
Otros nombres:
Correlative studies
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Safety / Tolerability (type, frequency, severity, and relationship of adverse events to study drug)
Periodo de tiempo: Courses repeat every 28 days in the absence of unacceptable toxicity.
|
Courses repeat every 28 days in the absence of unacceptable toxicity.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Time to progression of disease
Periodo de tiempo: Courses repeat every 28 days in the absence of disease progression .
|
Courses repeat every 28 days in the absence of disease progression .
|
|
Tumor response according to RECIST
Periodo de tiempo: at the end of Cycle 2 and every 56 days thereafter until tumor progression
|
at the end of Cycle 2 and every 56 days thereafter until tumor progression
|
|
Lab correlatives (FCGRIIa and FCGRIIIa polymorphisms, K-Ras and B-Raf mutations)
Periodo de tiempo: Tissue collection less than or equal to 28 days prior to day 1 of therapy
|
FCGR2a and FCGR3a polymorphisms, K-Ras and B-Raf mutations in patient specimens (paraffin embedded formaldehyde fixed tissues) will be identified.
|
Tissue collection less than or equal to 28 days prior to day 1 of therapy
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Richard Kim, Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Colon
- Enfermedades intestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Neoplasias colorrectales
- Neoplasias Rectales
- Neoplasias colónicas
- Efectos fisiológicos de las drogas
- Agentes antineoplásicos
- Factores inmunológicos
- Inhibidores de la angiogénesis
- Agentes moduladores de la angiogénesis
- Sustancias de crecimiento
- Inhibidores del crecimiento
- Anticuerpos
- Lenalidomida
- Inmunoglobulinas
- Anticuerpos Monoclonales
- Agentes antineoplásicos inmunológicos
- Cetuximab
Otros números de identificación del estudio
- CASE8208 (Otro identificador: Case Comprehensive Cancer Center)
- NCI-2010-01202 (Otro identificador: National Cancer Institute)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de recto
-
ColubrisMXActivo, no reclutandoPólipo rectal | Lesión rectal | Adenoma rectalEstados Unidos
-
Groupe Hospitalier Paris Saint JosephTerminado
-
Instituto de Investigación Hospital Universitario...ReclutamientoCirugía Rectal OncológicaEspaña
-
Technische Universität DresdenReclutamiento
-
Arrowhead Regional Medical CenterTerminadoCuerpo extraño rectal | Perforación rectal | Perforación colónicaEstados Unidos
-
Assistance Publique - Hôpitaux de ParisReclutamientoTransporte rectal de enterobacterias productoras de carbapenemasasFrancia
-
Université de SherbrookeTerminadoDisfunción sexual | Satisfacción del paciente | Cirugia Rectal
-
Stanford UniversityCaring for Carcinoid Foundation; GI Cancer Research Gift FundRetiradoNeoplasias Gastrointestinales | Cancer de pancreas | Cáncer de ano | Cáncer de colon/rectal | Cánceres hepatobiliares | Cáncer gástrico (de estómago) | Cánceres ginecológicos | Cáncer de la unión gastroesofágica (GE) | Cánceres ginecológicos Cáncer de cuello uterino | Tumor del estroma gastrointestinal... y otras condicionesEstados Unidos
-
University Hospital OstravaTerminadoCirugía Abdominal Mayor | Duodenohemipancreatectomía | Resección rectal | Cirugía Intestinal ExtensaRepública Checa
-
Mansoura UniversityTerminadoProlapso rectal completoEgipto
Ensayos clínicos sobre cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterReclutamientoCarcinoma de células escamosas de cabeza y cuello | Evaluación de margenPaíses Bajos
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityReclutamientoCáncer colonrectal | Capecitabina | CetuximabPorcelana
-
Eben RosenthalNational Cancer Institute (NCI)TerminadoAdenocarcinoma de páncreasEstados Unidos
-
HiberCell, Inc.TerminadoCáncer colonrectalEstados Unidos, Puerto Rico, Alemania, Francia
-
Merck KGaA, Darmstadt, GermanyTerminadoCáncer colorrectal metastásico no tratado previamenteFrancia, Italia, Polonia, Alemania, Hong Kong, Austria, Brasil, Israel, Grecia, Argentina, Tailandia, Bélgica, Australia, México
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCTerminadoCáncer colorrectal metastásicoAustria
-
Cancer Institute and Hospital, Chinese Academy...Reclutamiento
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenTerminadoCáncer colorrectal metastásicoPaíses Bajos
-
Poitiers University HospitalTerminadoCáncer de colon metastásicoFrancia
-
Copenhagen University Hospital at HerlevDesconocido